Werewolf Therapeutics Engages Piper Sandler to Explore Sale, Merger, Licensing
Werewolf Therapeutics has engaged Piper Sandler to evaluate strategic alternatives, including sale, merger, asset sale, licensing or collaboration, to maximize stockholder value. The company’s platforms, including clinical-stage INDUKINE INDUCER candidates WTX-124, WTX-330 and earlier-stage molecules, underpin these discussions.
1. Strategic Alternatives Exploration
Werewolf Therapeutics has launched a strategic review process by engaging Piper Sandler & Co. as exclusive financial advisor. The board will assess options such as sale, merger, asset divestiture, licensing or collaborations with no defined timeline or guarantee of transaction.
2. Pipeline and Platforms
The evaluation leverages Werewolf’s proprietary PREDATOR-derived INDUKINE and INDUCER technologies. Lead clinical-stage candidates WTX-124 and WTX-330 target solid tumors via conditionally activated IL-2 and IL-12, while earlier-stage molecules support potential asset and licensing discussions.